Intensity Therapeutics, Inc. (NASDAQ: INTS)

Sector: Healthcare Industry: Biotechnology CIK: 0001567264
Market Cap 4.10 Mn
P/B 0.57
P/E -0.35
P/S 0.00
ROIC (Qtr) -251.04
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 87,000.00
Debt/Equity (Qtr) 0.01
Add ratio to table...

About

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, is dedicated to developing novel, localized cancer reduction therapies that lead to anti-cancer immune activation (Intensity Therapeutics, Inc.). The company's main business activities revolve around the creation of innovative treatments for cancer, with a focus on realizing the full potential of its primary product candidate, INT230-6, in metastatic and local disease settings. Intensity Therapeutics operates within the biotechnology industry and conducts its operations primarily...

Read more

Investment thesis

Bull case

  • Strong tangible asset base of 9.59M provides 110.17x coverage of total debt 87000, indicating robust asset backing and low credit risk.
  • Tangible assets of 9.59M provide robust 16.19x coverage of other current liabilities 592000, indicating strong asset backing.
  • Strong cash position of 7.07M provides 11.94x coverage of other current liabilities 592000, indicating excellent liquidity.
  • Cash reserves of 7.07M provide robust 3.11x coverage of current liabilities 2.28M, indicating strong short-term solvency.
  • Robust R&D investment of 7.25M at 1.52x of SG&A 4.79M demonstrates strong commitment to innovation and future growth.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 7.25M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (9.50M) shows concerning coverage of stock compensation expenses of 2.39M, with a -3.97 ratio indicating potential earnings quality issues.
  • Operating earnings of (11.74M) show weak coverage of depreciation charges of 25000, with a -469.44 ratio indicating high capital intensity and potential reinvestment needs.
  • High financing cash flow of 13.79M relative to working capital of 5.91M, which is 2.33x suggests concerning dependence on external funding for operational needs.
  • Operating cash flow of (9.50M) is outpaced by equity issuance of 13.79M (-0.69 ratio), indicating concerning reliance on equity markets for funding operations.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.21 11.06
EV to Cash from Ops. EV/CFO -0.21 26.32
EV to Debt EV to Debt 22.73 762.61
EV to EBIT EV/EBIT -0.17 -13.49
EV to EBITDA EV/EBITDA -0.16 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -0.21 25.66
EV to Market Cap EV to Market Cap 0.48 203.37
EV to Revenue EV to Revenue 0.00 156.31
Price to Book Value [P/B] P/B 0.57 20.59
Price to Earnings [P/E] P/E -0.35 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 154.03 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 27.82 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 28.12 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) 27.82 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 27.82 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 41.12 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) 29.62 -40.48
Gross Profit Growth (1y) % Gross Profit Growth (1y) % 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 3.11 3.92
Current Ratio Curr Ratio (Qtr) 3.60 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.01 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % 0.00 -17,888.70
EBIT Margin % EBIT Margin % 0.00 -18,246.34
EBT Margin % EBT Margin % 0.00 -19,108.08
Gross Margin % Gross Margin % 0.00 -10.30
Net Profit Margin % Net Profit Margin % 0.00 -19,056.96